These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27566738)

  • 21. Institutionalizing Health Technology Assessment in Brazil: Challenges Ahead.
    Kuchenbecker R; Polanczyk CA
    Value Health Reg Issues; 2012 Dec; 1(2):257-261. PubMed ID: 29702910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Access to vaccines in Brazil and the global dynamics of the Health Economic-Industrial Complex.
    Gadelha CAG; Braga PSDC; Montenegro KBM; Cesário BB
    Cad Saude Publica; 2020; 36 Suppl 2():e00154519. PubMed ID: 32876097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Assessment of innovations in clinical research: strengths and potentials for improvement of research in Germany].
    Vollmar HC; Georgieff P; Bührlen B
    Z Evid Fortbild Qual Gesundhwes; 2010; 104(10):738-43. PubMed ID: 21147437
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence and Access to Biomedical Interventions: The Case of Stem Cell Treatments.
    Maschke KJ; Gusmano MK
    J Health Polit Policy Law; 2016 Oct; 41(5):917-37. PubMed ID: 27256806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The judicialization of health in the Federal District of Brazil].
    Diniz D; Machado TR; Penalva J
    Cien Saude Colet; 2014 Feb; 19(2):591-8. PubMed ID: 24863835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brazil's health system woes worsen in economic crisis.
    Watts J
    Lancet; 2016 Apr; 387(10028):1603-4. PubMed ID: 27116057
    [No Abstract]   [Full Text] [Related]  

  • 27. Between the court and the clinic: lawsuits for medicines and the right to health in Brazil.
    Biehl J; Amon JJ; Socal MP; Petryna A
    Health Hum Rights; 2012 Jun; 14(1):E36-52. PubMed ID: 22773096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethical issues on the "synthetic" phosphoethanolamine clinical trial.
    Paumgartten FJR
    Rev Assoc Med Bras (1992); 2017 May; 63(5):388-392. PubMed ID: 28724033
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The republic in crisis and future possibilities.
    Domingues JM
    Cien Saude Colet; 2017 Jun; 22(6):1747-1758. PubMed ID: 28614496
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The public production of medicines compared to the National Policy of Medicines and the burden of disease in Brazil.
    Figueiredo TA; Schramm JMA; Pepe VLE
    Cad Saude Publica; 2017 Sep; 33(9):e00179815. PubMed ID: 28977283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Explaining Brazil as a rising state, 2003‒2014: the role of policy diffusion as an international regulatory instrument.
    Menezes H; Vieira M
    J Int Relat Dev (Ljubl); 2022; 25(1):107-128. PubMed ID: 34054334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The decision-making process in Brazil's ratification of the World Health Organization Framework Convention on Tobacco Control.
    Rangel EC; Pereira A; Cavalcante TM; Oliveira EA; Silva VLDCE
    Cad Saude Publica; 2017 Sep; 33Suppl 3(Suppl 3):e00126115. PubMed ID: 28954054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. We are all people living with AIDS: myths and realities of AIDS in Brazil.
    Daniel H
    Int J Health Serv; 1991; 21(3):539-51. PubMed ID: 1917212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. National guidelines for high-cost drugs in Brazil: achievements and constraints of an innovative national evidence-based public health policy.
    Picon PD; Beltrame A; Banta D
    Int J Technol Assess Health Care; 2013 Apr; 29(2):198-206. PubMed ID: 23552016
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Harmonization of reimbursement and regulatory approval processes: a systematic review of international experiences.
    Tsoi B; Masucci L; Campbell K; Drummond M; O'Reilly D; Goeree R
    Expert Rev Pharmacoecon Outcomes Res; 2013 Aug; 13(4):497-511. PubMed ID: 23977976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brazil's Mixed Public and Private Hospital System.
    Lewis M; Penteado E; Malik AM
    World Hosp Health Serv; 2015; 51(2):22-6. PubMed ID: 26521382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brazilian pharmaceutical diplomacy: social democratic principles versus soft power interests.
    Flynn M
    Int J Health Serv; 2013; 43(1):67-89. PubMed ID: 23527455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
    Botelho SF; Martins MA; Vieira LB; Reis AM
    J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
    Leyens L; Brand A
    Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Spotlight: Brazil.
    Carter M
    Popul Today; 1996 Aug; 24(8):7. PubMed ID: 12291548
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.